Vest Financial LLC decreased its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 5.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 225,194 shares of the medical instruments supplier's stock after selling 12,659 shares during the quarter. Vest Financial LLC owned approximately 0.08% of Becton, Dickinson and Company worth $51,583,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BDX. Charles Schwab Trust Co lifted its stake in shares of Becton, Dickinson and Company by 18.5% in the 1st quarter. Charles Schwab Trust Co now owns 1,284 shares of the medical instruments supplier's stock valued at $294,000 after purchasing an additional 200 shares in the last quarter. Chesley Taft & Associates LLC lifted its stake in shares of Becton, Dickinson and Company by 97.7% in the 1st quarter. Chesley Taft & Associates LLC now owns 68,522 shares of the medical instruments supplier's stock valued at $15,696,000 after purchasing an additional 33,860 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. lifted its stake in shares of Becton, Dickinson and Company by 32.0% in the 1st quarter. Thurston Springer Miller Herd & Titak Inc. now owns 6,125 shares of the medical instruments supplier's stock valued at $1,403,000 after purchasing an additional 1,484 shares in the last quarter. Boltwood Capital Management lifted its stake in shares of Becton, Dickinson and Company by 12.0% in the 1st quarter. Boltwood Capital Management now owns 1,217 shares of the medical instruments supplier's stock valued at $279,000 after purchasing an additional 130 shares in the last quarter. Finally, Fermata Advisors LLC acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at about $202,000. Hedge funds and other institutional investors own 86.97% of the company's stock.
Insider Buying and Selling at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, EVP Richard Byrd sold 459 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $230.00, for a total value of $105,570.00. Following the sale, the executive vice president now directly owns 6,952 shares of the company's stock, valued at $1,598,960. This trade represents a 6.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP David Shan sold 1,166 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the sale, the executive vice president now directly owns 4,575 shares in the company, valued at $783,194.25. This represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 4,044 shares of company stock valued at $836,000 in the last three months. Corporate insiders own 0.36% of the company's stock.
Becton, Dickinson and Company Stock Up 1.4%
Shares of BDX traded up $2.44 during trading on Friday, reaching $173.47. The company's stock had a trading volume of 2,036,193 shares, compared to its average volume of 1,943,102. The company has a fifty day moving average of $186.95 and a two-hundred day moving average of $214.84. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The company has a market cap of $49.72 billion, a price-to-earnings ratio of 28.82, a P/E/G ratio of 1.63 and a beta of 0.25. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. The company had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same period in the prior year, the company posted $3.17 EPS. Becton, Dickinson and Company's quarterly revenue was up 4.5% on a year-over-year basis. On average, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.40%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company's payout ratio is 79.39%.
Analysts Set New Price Targets
Several research firms have recently weighed in on BDX. Bank of America lowered Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price objective on the stock. in a research note on Thursday, May 1st. Stifel Nicolaus reduced their price objective on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. The Goldman Sachs Group cut Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target for the company. in a report on Friday, May 2nd. Morgan Stanley decreased their price target on Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating for the company in a report on Tuesday, May 6th. Finally, Wall Street Zen cut Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company has an average rating of "Hold" and a consensus target price of $219.22.
Check Out Our Latest Stock Report on BDX
Becton, Dickinson and Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Recommended Stories
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
